Revolution Medicines Inc
(NAS:RVMD)
$
58.58
-0.05 (-0.09%)
Market Cap: 9.85 Bil
Enterprise Value: 8.39 Bil
PE Ratio: 0
PB Ratio: 6.27
GF Score: 43/100 Revolution Medicines Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022 / 08:30PM GMT
Release Date Price:
$21.14
(-6.25%)
Michael Schmidt
Guggenheim Securities, LLC - Analyst
Hello. My name is Michael Schmidt. I'm a biotech research analyst with Guggenheim Securities. And it's my great pleasure to welcome Mark Goldsmith, CEO of Revolution Medicines. Welcome, Mark, and thanks for joining us.
Mark Goldsmith
Revolution Medicines, Inc. - President, CEO & Board Chairman
Thanks, Michael, really appreciate the opportunity.
Questions & Answers
Michael Schmidt
Guggenheim Securities, LLC - Analyst
Revolution Medicines is perhaps the most advanced company pursuing development of so-called RAS(ON) inhibitors or RAS GTP inhibitors, which is different from what others are doing at the moment. And so can you just help us understand why that is important and what the underlying mechanism of your pipeline in that regard is?
Mark Goldsmith
Revolution Medicines, Inc. - President, CEO & Board Chairman
Sure. When we refer to RAS-dependent cancers, which of course, is the focus of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot